Trials / Completed
CompletedNCT01673724
Pramipexole and Bromocriptine on Nonmotor Symptoms of Early Parkinson's Disease
Effect of Pramipexole and Bromocriptine on Nonmotor Symptoms of Early Parkinson's Disease: Multicenter, Open-label, Parallel, Randomized Study
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 121 (actual)
- Sponsor
- Sandoz · Industry
- Sex
- All
- Age
- 30 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether pramipexole and bromocriptine are effective in the treatment of non-motor symptoms in Parkinson's Disease.
Detailed description
PRIMARY OBJECTIVE Evaluate the Improvement of Nonmotor symptom scale (NMSS) between Pramipexole and Bromocriptine for early Parkinson's disease during 24-week treatment SECONDARY OBJECTIVE * Evaluate the improvement for Depression which is one of the Nonmotor symptoms * Evaluate the improvement of clinical symptoms between two groups * Evaluate the improvement of Quality of Life between two groups
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | pramipexole | pramipexole |
| DRUG | Bromocriptine | bromocriptine |
Timeline
- Start date
- 2012-02-01
- Primary completion
- 2016-05-23
- Completion
- 2016-05-23
- First posted
- 2012-08-28
- Last updated
- 2017-09-15
Locations
7 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01673724. Inclusion in this directory is not an endorsement.